A method for producing a sugar anhydride, said method comprising: (1) a step for conducting a first heat treatment by heating a polysaccharide having a reducing end at 130-350° C. in the presence of an alcohol compound having 1-10 carbon atoms and not having an acetal structure; (2) a step for conducting a second heat treatment by heating the polysaccharide having been heated in the first heat treatment and thus thermally decomposing the polysaccharide to thereby give a gaseous sugar anhydride, without forming a char or with forming a filmy char, and without generating carbon monoxide or with regulating the generation amount of carbon monoxide, if any, to not more than 5 parts by mass per 100 parts by mass of the absolute dry mass of the polysaccharide; and (3) a collection step for cooling the gaseous sugar anhydride to a temperature equal to or lower than the boiling point thereof and then collecting the same. According to this method, a sugar anhydride can be easily produced at a high yield.

A method for producing a sugar anhydride, said method comprising: (1) a step for conducting a first heat treatment by heating a polysaccharide having a reducing end at 130-350° C. in the presence of an alcohol compound having 1-10 carbon atoms and not having an acetal structure; (2) a step for conducting a second heat treatment by heating the polysaccharide having been heated in the first heat treatment and thus thermally decomposing the polysaccharide to thereby give a gaseous sugar anhydride, without forming a char or with forming a filmy char, and without generating carbon monoxide or with regulating the generation amount of carbon monoxide, if any, to not more than 5 parts by mass per 100 parts by mass of the absolute dry mass of the polysaccharide; and (3) a collection step for cooling the gaseous sugar anhydride to a temperature equal to or lower than the boiling point thereof and then collecting the same. According to this method, a sugar anhydride can be easily produced at a high yield.

Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.

##STR00001##

Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.

##STR00001##

A .sup.99mTc-labeled isonitrile-containing glucose derivative having the general formula [.sup.99mTc-(CNDG).sub.6].sup.+, preparation method and use thereof is disclosed herein. The derivative is centered on .sup.99mTc.sup.+, and the carbon atom of the isonitrile in CNDG coordinates with .sup.99mTc(I) to form a hexacoordinated complex [.sup.99mTc-(CNDG).sub.6].sup.+. The [.sup.99mTc-(CNDG).sub.6].sup.+ derivative was obtained by the synthesis of the ligand CNDG and the preparation of the lyophilized CNDG kit. The derivative of this disclosure has good stability, simple preparation, high uptake and good retention at a tumor site, and high tumor/non-target ratio, and it is a novel .sup.99mTc-labeled isonitrile-containing glucose derivative with excellent performance for tumor imaging. The derivative of this disclosure is advantageous for popularization and application.

Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene L-proline monohydrate.

Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene L-proline monohydrate.

Provided herein are compositions, devices, systems and methods for generation and use of biomolecule-based information for storage. Further provided are devices comprising addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.) Further provided are compositions for low voltage deprotection of polynucleotides.

The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.